WE’VE MASTERED ADC & VACCINE INNOVATION.
Privately owned biopharmaceutical contract research organization that extends its services to the pharmaceutical industry and maintains an internal research and development department. While our primary focus centers around ADC and vaccines, our expertise extends far beyond these areas through our unique proof of concept in bioconjugation, we have the power to revolutionize the ADC and vaccine landscape.
#why-INVESTING NOW OUR UNIQUE PROOF OF CONCEPT
WASSC has recently achieved a remarkable and distinctive proof of concept in the realm of ADCs payload bioconjugation. Through this groundbreaking technology, we can now successfully conjugate payloads to four different sites on an antibody, resulting in one of the first multi-payload ADCs. This advancement enables a more homogeneous production of our ADCs, ensuring precise control over drug-to-antibody ratios (DAR), site of conjugation, and the biochemical properties of the complex.
“WE’RE READY TO BRING THIS APPROACH FURTHER
TAG ALONG FOR GREAT RETURN ON INVESTMENT
Multisite Specific conjugation : Our new technology enables the production of homogeneous ADC. This means using conjugation aids to target pre-determined sites on the antibody, giving optimal, reproductible ADC production.
The selection of the conjugation site profoundly impacts the biochemical and pharmacodynamic characteristics of the antibody. This targeted approach simplifies the characterization process, resulting in reduced complexity and increased efficiency. Additionally, it leads to cost savings in ADC production, as it entails fewer constraints on machinery, equipment, and manpower requirements.
Our technology offers a notable advantage beyond optimizing the conjugation site. It allows for site-specific conjugation without the need for genetic engineering, resulting in improved drug-to-antibody ratios (DARs) while maintaining the integrity of the antibody. This approach ensures a more precise and effective ADC production, enhancing the overall performance of the therapeutic complex.
Built on basic protein principles, our technology applies to various applications that stretches far beyond ADCs.
We can apply our technologies to any protein of interest
$528B Dollars
market by 2025
– 13.8% CAGR from 2018 to 2025 vs. 3-6% for the global pharmaceuticals
– here to create amazing returns ON INVESTMENTS
Specializing in ADC design, we specialize in site linking, and positioning, we can turn any drug into an ADC, we’ve found a major key – time for you to tag along and invest in one of the fastest growing ADC startup company. Market of $211B by 2031.
Register for an investor meeting Would you like to know more how you can benefit from investing into WASSC Tech, fill out the below form, and we will get in touch with you to set up an investor meeting. Click here to our science benefits.“WE'RE READY TO BRING
THIS APPROACH FURTHERTAG ALONG FOR GREAT RETURN ON INVESTMENT
